ArticleFrontiers in neurology
Vagus nerve stimulation for treating refractory epilepsy with myoclonic seizures in children.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the efficacy, tolerability, and safety of vagus nerve stimulation (VNS) in pediatric refractory epilepsy with myoclonic seizures. Methods: We conducted a retrospective monocentric study at a pediatric center specializing in myoclonic seizures. This study included 19 children (13 males, 6 females; mean age 5.8 years, range: 2-14 years) who underwent VNS implantation between January 2019 and July 2025. Myoclonic seizures were confirmed by video electroencephalogram (v-EEG). The median number of Anti-seizure Medications (ASMs) at implantation was 3.1 (IQR: 2-4). The mean follow-up duration was 31 months (range: 12-56 months). Results: Patients exhibited various seizure types, including infantile spasms, myoclonic, myoclonic-tonic, generalized tonic-clonic, generalized tonic, and focal seizures. At the last follow-up, 10 patients (52.6%) achieved ≥50% seizure reduction, and 4 (21.1%) attained seizure freedom. The seizure freedom rate was 31.6% for myoclonic seizures. Significance: VNS demonstrates promise as a safe and effective treatment for pediatric refractory epilepsy (PRE). The seizure freedom rate for myoclonic seizures was particularly noteworthy. These findings suggest that VNS should be considered an early intervention to optimize myoclonic seizure control outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.